Colorectal cancer is the third most common cancer in men and the second in women, according to the International Agency for Research on Cancer. Almost 60 percent of the cases occur in developed regions. About 608,000 deaths from colorectal cancer are estimated worldwide annually, accounting for 8 percent of all cancer deaths and making it the fourth most common cause of death from cancer. In the United States, colorectal cancer is the third most common and the second leading cause of cancer death.
In addition to the financial investment and as part of a broader collaboration, Check-Cap and GE Healthcare have entered into a development and supply agreement where GE Healthcare?Israel will develop, design and produce miniature Cadmium Zinc Telluride (CZT) diagnostic imaging sensors inside each Check-Cap capsule to enable clinicians to obtain full 360-degree imaging as the capsule travels in the colon. GE has years of experience in the area of CZT-based detectors and similar technologies have been used in GE Healthcare's nuclear medicine and bone densitometry systems.
"Over the past 15 years GE Healthcare has benefited from Israel's spirit of innovation and scientific discoveries," said Oded Meirav, manager of the GE Global Research?Israel Technology Center. "Seeking partnerships between a global company such as GE and Israeli high-tech companies like Check-Cap can truly be a win-win for all. This represents the first GE healthymagination Fund investment in Israel."
The investment in Check-Cap reflects GE Healthcare's continuing interest in innovative clinical stage healthcare technologies. As an investor, GE Healthcare will look for various ways to work with Check-Cap that complement the strategic objectives of its healthymagination initiative.
Source: http://usmolecular.com/2012/4141
juelz santana greg halman greg halman dancing with the stars results ucla basketball walmart black friday sales walmart black friday sales
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন